Published in Lab Business Week, November 5th, 2006
According to a study from Japan, "Docetaxel has shown activity in elderly patients with advanced NSCLC. This randomized phase III trial evaluated the efficacy and safety of docetaxel versus vinorelbine (the current standard treatment) in elderly patients. Chemotherapy-naive patients age 70 years or older with stage IIIB/IV NSCLC and performance status 2 or lower were eligible."
"Patients randomly received docetaxel...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.